China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to accelerate biomarker-driven clinical studies and explore the cutting edge of companion diagnostics (CDx) development. Financial details of the partnership were not disclosed.
Clinical and Development Context
With the deepening of research on tumor pathogenesis, immunotherapy, particularly immune checkpoint inhibitors (ICIs), has emerged as one of the most promising treatment methods. However, the overall response rate of ICIs remains low, and the beneficiary population is very limited. As a result, the concurrent development of drug companion diagnostics (CDx) has become essential during clinical trials. This partnership aims to address these challenges by leveraging advanced biomarker research and diagnostic capabilities.-Fineline Info & Tech
